Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.

A woman's shingles infection triggered her first episode of a rare neurological disorder and blood vessel inflammation.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Biopsy can differentiate between alopecia areata and androgenic alopecia, and if more information is needed, testing for CD3 and CD8 can help.

Low-dose chemotherapy is safer, more effective, and cost-effective than surgery for treating bone lesions in children.

The document concludes that early diagnosis of Balint's syndrome is crucial for effective treatment and that understanding drug interactions, like between ritonavir and statins, is important for patient care.

Upadacitinib effectively treated severe hair loss in a child.

Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.

Cell adhesion molecules are important in the development of certain skin diseases.

ULBP3 could be a marker for diagnosing alopecia areata incognita and may be linked to its cause and development.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

A possible link exists between minimal change nephrotic syndrome and complete hair loss.

Isolated limb perfusion is a safe and effective treatment for limb melanoma.

A woman's sudden hair loss three years after a bone marrow transplant was a sign of chronic graft-versus-host disease but improved with treatment.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Azole antifungals can cause skin reactions like EAC, requiring careful management.

Purpura fulminans can signal underlying autoimmune disorders, not just infections.

Lower GATA3 levels in mice help hair regrow by changing certain immune cells.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Painful hair loss in an elderly woman was caused by giant cell arteritis, not just aging.

Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.